Quininib

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 2620

CAS [143816-42-6]

MF C17H13NO
MW 247.29

  • Purity: 99%
  • Soluble in DMSO

Quininib

Description

Antagonist of the cysteinyl leukotriene receptor 1 and 2 (CysLT1-2; IC50 values 1.4 μM and 38.5 μM, respectively). Quininib robustly inhibits developmental angiogenesis in zebrafish (at 4-10 μM), and significantly inhibits angiogenic tubule formation in HMEC-1 cells, angiogenic sprouting in aortic ring explants and retinal revascularisation in OIR mice, independently of VEGF receptors. Moreover, using ex vivo human CRC explants, Quininib significantly reduced the secretions of angiogenic growth factors and inflammatory cytokines IL-6, IL-8, VEGF, ENA-78, GRO-α, TNF, IL-1β and MCP-1.

KEYWORDS: Quininib | supplier | CysLT antagonist | 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol | CAS [143816-42-6] | Cysteinyl leukotrienes | CysLT1 | CysLT2 | GPCR | VEGF | angiogenesis | LTD4 | LTE4 | blood vessels | retina | ocular | colorectal cancer | CRC

Order
Size Unit Price Stock
10 mg €95.00 In Stock
50 mg €350.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...